State of the Art Symposium
SA 1 - Artificial intelligence (AI) in clinical practice: life past the hype
Lectures
1
Chairperson's introduction
05:00Merel Huisman, Nijmegen / NL
2
Clinical AI products in body imaging: an overview
15:00Renato Cuocolo, Naples / IT
3
EU Artificial Intelligence Act: impact on medical imaging
15:00Hugh Harvey, Banstead / UK
4
Raising the bar: clinical trials for healthcare AI products
15:00Ritse Mann, Nijmegen / NL
5
Post-market surveillance for artificial intelligence
15:00Stephan Romeijn, Utrecht / NL
6
Panel discussion: The AI act: friend or foe?
25:00Panel discussion: The AI act: friend or foe?
5 min
Chairperson's introduction
Merel Huisman, Nijmegen / Netherlands
15 min
Clinical AI products in body imaging: an overview
Renato Cuocolo, Naples / Italy
- To discuss some of the more common clinical applications of AI in body imaging.
- To analyse limitations emerging from the clinical implementation of AI software.
- To consider potential strategies to improve the clinical impact of AI in body imaging.
15 min
EU Artificial Intelligence Act: impact on medical imaging
Hugh Harvey, Banstead / United Kingdom
- To learn about the specific regulations within the EU Artificial Intelligence Act that pertain to medical imaging applications.
- To appreciate the ethical considerations and patient safety measures introduced by the Act.
- To understand the broader impacts of the Act on innovation, research, and clinical practice within the field of medical imaging across Europe.
15 min
Raising the bar: clinical trials for healthcare AI products
Ritse Mann, Nijmegen / Netherlands
- To understand the types of studies common in AI imaging tools.
- To be able to define the value of research results for AI in imaging in a clinical context.
- To discuss minimal validation standards before and during the implementation of AI in imaging.
15 min
Post-market surveillance for artificial intelligence
Stephan Romeijn, Utrecht / Netherlands
- To recognise the importance of post-market surveillance for AI in radiology, ensuring ongoing safety and effectiveness.
- To identify challenges in post-market surveillance, focusing on data integrity and adherence to regulations.
- To explore methodologies for effective surveillance, such as generating real-world evidence and implementing proactive risk management strategies.
25 min
Panel discussion: The AI act: friend or foe?
Merel Huisman
Nijmegen / Netherlands
Merel Huisman
Nijmegen / NetherlandsRenato Cuocolo
Naples / ItalyHugh Harvey
Banstead / United KingdomRitse Mann
Nijmegen / NetherlandsStephan Romeijn
Utrecht / Netherlands